candidate

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Bitcoin, which goes hand in hand with AI technology, can we expect a continued bright outlook? 

Source Node:
Time Stamp: January 11, 2024 11:30 AM - Modified On: January 11, 2024 - Published By:
Source Cluster:
Republished By Plato

Due to the full-scale introduction of AI technology in 2023, America's big tech companies such as Meta, Amazon, and Twitter are threatening human jobs by laying off more than 100,000 employees a year alone. In the aftermath of this, some experts say that the pace of AI development should be slowed down to prevent further harm to human jobs, but on the other hand, most experts believe that human development should proceed together in a society that coexists with AI, rather than slowing it down. There was also an opinion

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

TruthGPT A Revolutionary Language Model Set to Change the Game

Source Node:
Time Stamp: May 1, 2023 5:43 AM - Modified On: May 2, 2023 - Published By:
Source Cluster:
Republished By Plato

In recent years, natural language processing (NLP) has become a buzzword in the world of technology. With the increasing demand for AI-powered chatbots, virtual assistants, and content creation tools, companies are investing heavily in developing more advanced NLP systems. However, with the help of TruthGPT, the future may offer some light on the capabilities of biased AI models, despite their ability to sow social discontent, promote cultural differences, and create barriers around a more friendly and inviting globalized civic society. The Fate So Far: The Rise of Artificial Intelligence Chatbots

Become a Distinguished Certification Holder by Passing Microsoft AZ-140 Exam

Source Node:
Time Stamp: April 23, 2022 3:30 PM - Modified On: April 23, 2022 - Published By:
Source Cluster:
Republished By Plato

Do you have a solid experience in Azure administration? Or perhaps an extensive background in working with virtual desktop apps and solutions in an Azure setup? Level up your skills by completing the Microsoft 70-480 and earning the acclaimed Microsoft Certified: Azure Virtual Desktop Specialty certification. But before you do so, it’s important that you know the entirety of the exam, from the main audience to the relevant study resources. Learn the basics First of all, Microsoft 70-486 serves as the main requirement for the Microsoft Certified: Azure Virtual Desktop